Robotic Arm System Automates Cell Therapy Manufacturing Steps

Modular robotics enter cell therapy production

A robotic system designed to automate portions of cell therapy manufacturing has been described in a September 2024 paper in the journal Cytotherapy, offering one approach to scaling production without replacing existing equipment platforms.

The system combines a robotic arm with customized modules that interface with standard cell therapy tools—incubators, bioreactors, and reagent bags—according to researchers from academic and industry laboratories. In testing, the robotic cluster produced human CD8+ T cells with cell yields, viability, and identity markers comparable to manually cultured cells while maintaining sterile conditions throughout the process.

Why it matters

Commercial autologous cell therapies, including CAR-T products, currently depend on labor-intensive manual processes that require specialized personnel. As more advanced therapies gain regulatory approval, the skilled workforce gap is widening. Modular automation systems that work with existing equipment represent a potentially faster path to scale than building entirely new manufacturing platforms—a critical consideration as production costs directly affect patient access to these treatments.

Addressing manufacturing bottlenecks

The Cytotherapy paper frames the robotic system as a response to specific industry constraints. Autologous cell therapy production today relies on complex manual workflows, and the authors note that skilled labor costs and scaling challenges contribute to high therapy prices.

A separate analysis published in Cytotherapy by researchers affiliated with the International Society for Cell & Gene Therapy and the European Society for Blood and Marrow Transplantation identified growing demand for trained production personnel as a manufacturing bottleneck, according to reporting by Genetic Engineering and Biotechnology News. That analysis pointed to automation and artificial intelligence as potential tools for addressing production challenges, particularly for allogeneic therapies that can be manufactured at larger volumes than patient-specific treatments.

Automation precedents in the field

A 2019 review in Biotechnology Letters characterized manual, planar culture-based production as labor-intensive and susceptible to batch-to-batch variability. That review outlined existing automated platforms, including robotic arm and incubator systems already deployed in academic and commercial settings for cell expansion tasks.

A March 2026 review in Pharmaceutics examined artificial intelligence and machine learning applications across cell and gene therapy development, from initial construct design through manufacturing and regulatory workflows, though the figures cited represent the authors' estimates rather than independently verified industry data.

Considerations for manufacturing facilities

For facilities evaluating automation investments, the published research suggests modular robotic systems designed to integrate with standard equipment offer one viable option. The Cytotherapy paper provides validated performance data—specifically, direct comparisons of cell yield and viability against manual processes—which represents the type of evidence manufacturing decision-makers should require before committing capital to automation platforms.

The robotic cluster described in the research demonstrates that automation can replicate manual culture performance without necessitating wholesale replacement of existing manufacturing infrastructure, a factor that may influence adoption timelines and capital planning in the cell therapy sector.

Details of the robotic system and performance data were first reported in the journal Cytotherapy and covered by MarketScale.